Business Wire

Aramco and Yokogawa Achieve a Major Milestone with Commissioning of Multiple Autonomous Control AI Agents at Major Gas Facility

29.10.2025 04:00:00 EET | Business Wire | Press release

Share

Yokogawa Electric Corporation (TOKYO: 6841, “Yokogawa”), a leader in process automation technology, announces it has achieved a historic milestone in the deployment of industrial artificial intelligence (AI) solutions with Aramco, one of the world’s leading integrated energy and chemicals companies. Multiple autonomous control AI*1 agents have been successfully implemented by Yokogawa at Aramco’s Fadhili Gas Plant in the Kingdom of Saudi Arabia to enhance operational efficiency.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028792329/en/

Fadhili Gas Plant (Courtesy of Aramco)

The AI solution developed by Yokogawa uses multiple, coordinated AI agents of the Factorial Kernel Dynamic Policy Programming (FKDPP)*2 reinforcement learning-based AI algorithm to directly and autonomously control and optimize acid gas removal (AGR) operations at the Fadhili Gas Plant.

The solution was introduced in three phases, progressively optimizing various sections until autonomous control of the core process in the AGR unit was achieved. To ensure safety, Yokogawa first created a simulator of the plant to train AI agents, and then evaluated their reliability and validity. Subsequently, they were integrated with Yokogawa's CENTUM VP integrated production control system to leverage the safety functions of the existing plant.

Implementation is currently undergoing a detailed evaluation, but initial results from Fadhili Gas Plant demonstrate a 10% to 15% reduction in its amine and steam usage, around 5% reduction in power usage, improved process stability, and a significant decrease in operator manual intervention, despite ambient condition changes.

Aramco Engineering Services Senior Vice President, Khalid Y. Al Qahtani, said: “Aramco has embarked on an ambitious plan to unlock value by deploying a wide range of industrial AI applications across our operations. The collaboration with Yokogawa is one of many initiatives that focus on improving efficiency, enhancing sustainability, and generating more value for our shareholders. It reflects how the company is harnessing advanced technology, including AI, to elevate its performance and reinforce its position as a technology leader in the energy sector. We look forward to building on this important milestone, as we explore further adoption of cutting-edge solutions that will contribute to a new era of industrial innovation.”

Kunimasa Shigeno, Director, President & CEO, and Representative Executive Officer of Yokogawa Electric, said: “We are honored that Yokogawa was entrusted by Aramco to implement such ground-breaking technology in one of its major facilities. We are very pleased that the results have already exceeded expectations. Yokogawa is advocating the transition from industrial automation to industrial autonomy (IA2IA), and this deployment proves that we are ready to lead the way towards safe and secure autonomous operations for plants in the energy sector.”

*1

Yokogawa defines autonomous control AI as AI that deduces the optimum method for control independently and has a high level of robustness enabling it to autonomously handle, to a certain extent, situations that it has not previously encountered.

*2

A reinforcement learning AI algorithm jointly developed by Yokogawa Electric and the Nara Institute of Science and Technology (NAIST). FKDPP received the Prime Minister's Prize at the 2023 Japan Industrial Technology Awards (Nihon Sangyo Gijyutsu Taisho).

About Aramco
As one of the world’s leading integrated energy and chemicals companies, our global team is dedicated to creating impact in all that we do, from providing crucial oil supplies to developing new energy technologies. We focus on making our resources more dependable, more sustainable and more useful, helping to promote growth and productivity around the world. https://www.aramco.com/

About Yokogawa
Yokogawa provides advanced solutions in the areas of measurement, control, and information to customers across a broad range of industries, including energy, chemicals, materials, pharmaceuticals, and food. Yokogawa addresses customer issues regarding the optimization of production, assets, and the supply chain with the effective application of digital technologies, enabling the transition to autonomous operations.
Founded in Tokyo in 1915, Yokogawa continues to work toward a sustainable society through its 17,000+ employees in a global network of 128 companies spanning 62 countries.
For more information, visit www.yokogawa.com.

The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of Aramco, Yokogawa Electric Corporation or their respective holders.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251028792329/en/

Contacts

Media enquiries
Yokogawa Electric Corporation
Public Relations Department, Integrated Communications Center
Tokyo, Japan
Yokogawa-pr@cs.jp.yokogawa.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye